drugset / Trial / NCT07374029
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatment of acute myeloid leukemia (AML). The names of the study drugs involved in this study are: * DC/AML fusion vaccine (immune cell vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone) * DC/AML Primed T cells (immune cells) * Decitabine (a type of chemotherapy drug) * Venetoclax (a type of antineoplastic agent)
Timeline
- Start
- 2026-02-12
- Primary completion
- 2027-10-01
- Completion
- 2030-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC/AML Fusion Vaccine | Vaccine | — | Subcutaneous |
| Subject | T-Cell Therapy | Cell therapy | — | Intravenous |
| Background | Decitabine | Small molecule | — | Intravenous |
| Background | Venetoclax | Small molecule | — | Oral |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |